Rheumatoid Arthritis Clinical Trial
— MDX1100-04Official title:
Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)
The purpose of this study is to:
1. determine the American College of Rheumatology (ACR) 20 response rate at Day 85 in
subjects with active rheumatoid arthritis(RA) administered MDX 1100 with methotrexate
(MTX); and
2. determine the tolerability and safety of multiple doses of MDX-1100 in combination with
MTX in subjects with active RA.
Status | Completed |
Enrollment | 70 |
Est. completion date | May 2009 |
Est. primary completion date | January 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Must meet the ACR criteria for RA - Must have active RA, characterized by at least 6 out of 66 swollen joints and 6 out of 68 tender joints, and at least 2 of the following: a serum C-reactive protein level greater than the upper limit of normal, an erythrocyte sedimentation rate >= 28 mm per hour, or morning stiffness > 45 minutes - Seropositive for rheumatoid factor, as defined by a plasma rheumatoid factor level of at least 20 IU per milliliter and/or be seropositive for anti-cyclic citrullinated peptide antibody - Must be on MTX (10 to 25 mg weekly) for at least 6 months receiving a stable dose for 42 days before randomization and no anticipated change in MTX dose while on study - Low-dose corticosteroids and NSAIDs are permitted at study entry and must have been stable for at least 28 days before randomization - All other disease modifying non-biologic anti-rheumatic drugs (DMARDs) must have been discontinued at least 28 days prior to randomization except for leflunomide (discontinued at least 60 days before randomization). Etanercept (discontinued at least 28 days prior to randomization) and infliximab, adalimumab, and abatacept (discontinued at least 56 days prior to randomization) - Screening laboratory values - Hemoglobin = 8.5 g/dL - White blood cell (WBC) = 3000/mm³ - Neutrophils = 1.5x10(9)/L - Platelets = 125x10(9)/L - Serum creatinine < 2 mg/dL - Aspartate aminotransferase (AST) = 2xULN - Alanine aminotransferase (ALT) = 2xULN - Women must be postmenopausal (> 12 months without menses) or surgically sterile or using effective contraception for at least 4 weeks prior to the anticipated Visit 2 date and agree to continue contraception for the duration of their participation in the study - Sexually active male subjects must use a barrier method of contraception during the course of the study. Exclusion Criteria: - Prior treatment with B cell depleting therapy - Any other monoclonal antibody or immunoglobulin-based fusion proteins = 8 weeks prior to randomization - Any other experimental treatment = 4 weeks prior to randomization - Primary or secondary immunodeficiency - Any other autoimmune disease other than RA (except concurrent Sjogren's syndrome or hypothyroidism) - Complications of RA including: - Active rheumatoid vasculitis - Bed bound or wheelchair bound - Clinically significant pulmonary fibrosis - Felty's syndrome - Any history of malignancy, excluding adequately treated and cured basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ - Active major psychiatric disease - Evidence of acute or chronic infection - Clinically significant cardiac disease requiring medication, unstable angina, myocardial infarction within 6 months of randomization, or congestive heart failure - Arrhythmia requiring active therapy, with the exception of clinically insignificant extrasystoles, or minor conduction abnormalities; - History of cerebrovascular disease requiring medication/treatment; - Concomitant anticoagulation therapy or a known bleeding disorder - Seizure disorder requiring active therapy - Known drug or alcohol abuse - Pregnant or nursing |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Romania | Brasov Clinical County Emergency Hospital Rheumatology Department | Brasov | |
Romania | "Dr. Carol Davila" Central Military Emergency Clinical Hospital | Bucharest | |
Romania | "Sf. Maria" Clinical Hospital, Department of Internal Medicine and Rheumatology | Bucharest | |
Romania | "Sf. Pantelimon" Emergency Clinical Hospital | Bucharest | |
Romania | Sana Medical Center | Bucharest | |
Romania | Cluj Emergency County Clinical Hospital Rheumatology Department | Cluj-Napoca | |
Romania | Rehabilitation Hospital, Rheumatology Department | Iasi | |
Romania | Targu-Mures County Clinical Hospital Rheumatology Department | Targu-Mures | |
Romania | SC Excentric Company SRL, Rheumatology Department | Timisoara | |
Ukraine | M. Gorky National Medical University | Donetsk | |
Ukraine | V.K. Gusak Institute of Urgent & Reconstructive Surgery within the Academy of Medical Sciences of Ukraine, Hospital Therapy and Rehabilitation Clinic | Donetsk | |
Ukraine | Kharkiv Medical Academy of Postgraduate Education, Department of Cardiology and Functional Diagnostics, Clinical Facility: City Clinical Hospital #8 | Kharkiv | |
Ukraine | Kyiv City Oleksandrivska Clinical Hospital, Rheumatology Department #2 | Kyiv | |
Ukraine | O.O. Bogomolets National Medical University, Department of Internal Diseases Propedeutics #2, Clinical facility: City Clinical Hospital #3 | Kyiv | |
Ukraine | Danylo Halytsky Lviv National Medical University, Department of Clinical Immunology and Allergology, Clinical Facility: Lviv Regional Clinical Hospital, Rheumatology Department | Lviv | |
Ukraine | Danylo Halytsky Lviv National Medical University, Department of Internal Diseases #2, Dermatology and Venerology within the Faculty of Continuing Education, Clinical facility: City Clinical Hospital #4, Rheumatology Department | Lviv | |
Ukraine | Public Institution O.I. Minakov City Clinical Hospital #9, Rheumatology Department | Odesa | |
Ukraine | Zaporizhya State Medical University, Department of Internal Diseases #2, Clinical facility: Medical and Sanitary Unit within the State-Owned Company "Radioprylad" | Zaporizhya |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
Romania, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ACR 20 Response rate | 85 days | No | |
Secondary | Safety and tolerability will be monitored by physical exam, laboratory tests, electrocardiograms, chest x-ray and adverse events experienced and reported by the patient | 141 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |